Market news

Bruker (NASDAQ:BRKR) CFO Gerald Herman said the company’s second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, while revenue came in later than anticipated. He attributed the revenue timing primarily to a mixed demand environment and shipment timing,

Shares of scientific instrument company Bruker (NASDAQ:BRKR) fell 6.3% in the afternoon session after UBS initiated coverage on the stock with a Neutral rating and a $65 price target.

Bruker (BRKR) has an average rating of overweight and mean price target of $51.58, according to anal

BILLERICA, Mass., September 08, 2026--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences:

On September 4, Bruker (NASDAQ:BRKR) said its energy and supercon technologies unit, Bruker Energy & Supercon Technologies (or BEST), had struck a supply collaboration with Luvata Materials & Solutions to scale up production of RRP superconductors for magnetic confinement fusion. The deal lands right as governments and private developers from Europe to South Korea race […]

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Let’s dig into the relative performance of Bruker (NASDAQ:BRKR) and its peers as we unravel the now-completed Q2 research tools & consumables earnings season.

Bruker’s second quarter results prompted a significant negative market reaction, with shares declining sharply following the release. Management identified several factors behind the top-line shortfall, notably the ongoing weakness in U.S. academic and government funding and revenue timing delays in certain deep tech areas, such as semiconductor metrology tools. CEO Frank Laukien described the organic growth as “solid in many life science end markets,” but highlighted that softness in U.S. acade

Detailed price information for Bruker Corp (BRKR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.

Bruker stock has had a strong run over the past year while the latest valuation work, including a Discounted Cash Flow (DCF) intrinsic value estimate and market multiple checks, still points to the shares trading at a discount to those fundamentals. Bruker has returned 57.6% over the past year, which puts extra focus on whether that share price move is now in line with the company’s underlying value. Recent acquisitions in life sciences, including the DISQVER metagenomic sequencing platform,...

Bruker Corporation’s Q2 2026 results, released on August 4, 2026, showed sales rising to US$838.5 million from US$797.4 million year over year, but a goodwill and intangible asset impairment charge of US$134.9 million and other items drove a net loss of US$52 million versus prior-year net income. The company reaffirmed a path to growth by guiding Fiscal Year 2026 revenues to US$3.54–US$3.57 billion, implying 3%–4% reported growth over 2025, while targeting cost savings and maintaining its...

Bruker (BRKR) just updated its 2026 revenue guidance alongside second quarter results, pairing a forecast of US$3.54b to US$3.57b in sales with a sizeable goodwill impairment and a reported quarterly net loss. See our latest analysis for Bruker. The sharp 1 day share price decline of 21.79% left Bruker trading at US$50.30, even though the 1 year total shareholder return is 57.62% and the 5 year total shareholder return is down 38.05%. This points to strong recent momentum but a weaker longer...

Moby summary of Bruker Corporation's Q2 2026 earnings call

Bruker Corp (BRKR) posts 5.2% revenue growth and 53% EPS jump, driven by strong biopharma and semiconductor orders despite U.S. academic weakness.

Detailed price information for Bruker Corp (BRKR-Q) from The Globe and Mail including charting and trades.

Bruker (NASDAQ:BRKR) returned to organic revenue growth in the second quarter, posted stronger bookings across its Scientific Instruments business, and maintained its earnings outlook while adjusting guidance for currency and tax changes. Key Investor TakeawaysBruker (NASDAQ:BRKR) returned to organic revenue growth, with second-quarter revenue increasing 5.

Bruker (NASDAQ:BRKR) reported second-quarter revenue growth and expanded profitability as demand improved for scientific instruments, particularly in biopharma and several “deep tech” markets including semiconductor metrology, security detection and energy research. Second-quarter reported revenue

The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Bruker (BRKR) delivered earnings and revenue surprises of +28.95% and -2.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

BILLERICA, Mass., August 04, 2026--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and six months ended June 30, 2026.

Scientific instrument company Bruker (NASDAQ:BRKR) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 5.2% year on year to $838.5 million. The company’s full-year revenue guidance of $3.56 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $0.49 per share was 27.5% above analysts’ consensus estimates.

Scientific instrument company Bruker (NASDAQ:BRKR) will be announcing earnings results this Tuesday before market open. Here’s what to look for.

BILLERICA, Mass., July 24, 2026--Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 2026. The Company will host a conference call and webcast at 9:00 a.m. Eastern Daylight Time to discuss the results and current business trends.

BREMEN, Germany, July 15, 2026--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.